Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Effects of injected leukemia inhibitory factor on hematopoietic and other tissues in mice.

Metcalf D., Nicola NA., Gearing DP.

Animal Study on Hip, published in Blood (1990) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Blood (1990)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
2114187

Abstract (original English)

Purified bacterially synthesized recombinant murine leukemia inhibitory factor (LIF) was injected in varying doses for up to 2 weeks into adult DBA/2 and C3H/HeJ mice. At high doses (2 micrograms, three times daily) LIF exhibited toxic effects seen as behavioral changes, loss of body fat, and thymus atrophy. Dose-related rises were observed in blood platelets, erythrocyte sedimentation rates, and serum calcium to albumin ratios, including dose schedules with no toxic effects. LIF induced a decrease in bone marrow cell numbers, particularly in marrow lymphocytes, and a moderate increase in spleen weight with a reduction in spleen lymphocytes and an elevation of erythroid populations. LIF-injected mice showed a rise in megakaryocytes up to twofold in the marrow and fivefold in the spleen, with an associated 10-fold rise in megakaryocyte progenitor cells in the spleen. Comparable rises in other types of progenitor cells were also observed in the spleen. The observed changes indicate the biologic activity of LIF in vivo and are consistent with the known wide range of in vitro actions of this molecule. The ability of LIF to elevate megakaryocyte and platelet levels suggests a potential clinical application of LIF in the treatment of thrombocytopenias.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueAnimalsBlood PlateletsBody WeightBone MarrowBone Marrow CellsCalciumDose-Response Relationship, DrugFemaleGrowth Inhibitors

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research